SAN MATEO, Calif. and CAMBRIDGE, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other ...
Data in the second half of 2023 could potentially lead to accelerated approvalIf approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit ...
Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results